Seres Therapeutics MCRB is gearing up to announce its quarterly earnings on Wednesday, 2024-11-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Seres Therapeutics will report an earnings per share (EPS) of $-0.24.
Seres Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Earnings History Snapshot
The company's EPS beat by $0.05 in the last quarter, leading to a 9.07% increase in the share price on the following day.
Here's a look at Seres Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.27 | -0.34 | -0.50 | -0.50 |
| EPS Actual | -0.22 | -0.27 | -0.32 | -0.37 |
| Price Change % | 9.0% | 37.0% | -5.0% | 39.0% |
Market Performance of Seres Therapeutics's Stock
Shares of Seres Therapeutics were trading at $0.6917 as of November 11. Over the last 52-week period, shares are down 46.78%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for Seres Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
